Forte Biosciences, Inc.

NasdaqCM FBRX

Forte Biosciences, Inc. Operating Income for the Trailing 12 Months (TTM) ending September 30, 2024: USD -35.63 M

Forte Biosciences, Inc. Operating Income is USD -35.63 M for the Trailing 12 Months (TTM) ending September 30, 2024, a -14.78% change year over year. Operating income is the profit earned by a company from its normal business operations before interest and taxes are deducted.

Forte Biosciences, Inc. Operating Income for the Trailing 12 Months (TTM) ending September 30, 2023 was USD -31.04 M, a -153.30% change year over year.
Forte Biosciences, Inc. Operating Income for the Trailing 12 Months (TTM) ending September 30, 2022 was USD -12.26 M, a 45.96% change year over year.
Forte Biosciences, Inc. Operating Income for the Trailing 12 Months (TTM) ending September 30, 2021 was USD -22.68 M, a 55.57% change year over year.
Forte Biosciences, Inc. Operating Income for the Trailing 12 Months (TTM) ending September 30, 2020 was USD -51.05 M.

Key data

Date	Operating Income	EBIT	EBITDA	Net Income

NasdaqCM: FBRX

Forte Biosciences, Inc.

CEO	Dr. Paul A. Wagner Ph.D.
IPO Date	April 13, 2017
Location	United States
Headquarters	3060 Pegasus Park Drive
Employees	11
Sector	Health Care
Industries Biotechnology Pharmaceuticals

Description

Forte Biosciences, Inc. operates as a clinical-stage biopharmaceutical company in the United States. It is developing FB-102 program that addresses various autoimmune diseases, such as vitiligo and alopecia areata. The company is headquartered in Dallas, Texas.

Key trends

Past 5 years